Miles will oversee the Santa Clara, California-based company’s commercialization strategy for the AccuCinch ventricular restoration system, a transcatheter procedure to treat enlarged left ventricles in the heart.
“Mark’s track record in commercialization and marketing of groundbreaking medical device therapies adds an important dimension of expertise to the Ancora Heart team,” said Jeff Closs, president and CEO of Ancora Heart. “While we are currently focused on enrollment in our pivotal trial, we also recognize the importance of looking forward with an ultimate goal of transitioning from clinical to commercial-stage, and we are thrilled to have Mark on board to drive this strategy.”
Miles has more than 25 years of experience scaling medical technology companies. He most recently was the chief commercial officer of Term Aortic where he was responsible for global sales and marketing, custom solutions, portfolio strategy and expansion into new markets. He has also held numerous roles within the medical device industry, including with Invuity, Medtronic and Eli Lilly and Company.
“I’m honored to be joining Ancora Heart as chief commercial officer, especially at this stage in the company’s development,” Miles said in a news release. “Ancora Heart’s innovative AccuCinch technology uniquely fills an important treatment gap for HFrEF patients, and I look forward to helping the Ancora Heart team establish a foundation for this tremendous opportunity in the continuum of heart failure care.”
